Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's EBIT?
- Avalo Therapeutics (AVTX) reported EBIT of -$31.52M in Q2 2026.
- How has Avalo Therapeutics's EBIT changed year-over-year?
- Avalo Therapeutics's EBIT decreased by 63.2% year-over-year, from -$19.32M to -$31.52M.
- What is the long-term trend for Avalo Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Avalo Therapeutics's EBIT has grown at a -2.9% compound annual growth rate (CAGR), from -$82.14M to -$72.93M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Avalo Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude